Analyst Price Targets — CLPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 4, 2026 12:41 pm | — | Lake Street | $25.00 | $12.42 | TheFly | ClearPoint Neuro price target lowered to $25 from $30 at Lake Street |
| August 4, 2026 10:56 am | Tom Stephan | Stifel Nicolaus | $22.00 | $15.38 | TheFly | ClearPoint Neuro price target lowered to $22 from $25 at Stifel |
| June 9, 2026 1:09 pm | Tom Stephan | Stifel Nicolaus | $16.00 | $13.47 | StreetInsider | Stifel Reiterates Buy Rating on Clearpoint Neuro Inc. (CLPT) |
| January 21, 2025 2:15 pm | Frank Takkinen | Lake Street | $30.00 | $15.44 | TheFly | ClearPoint Neuro price target raised to $30 from $17 at Lake Street |
| August 27, 2024 8:45 am | Frank Takkinen | Loop Capital Markets | $15.00 | $12.60 | StreetInsider | Clearpoint Neuro Inc. (CLPT) PT Raised to $15 at Lake Street Capital Markets |
| March 13, 2024 4:35 am | Mathew Blackman | Stifel Nicolaus | $9.00 | $7.17 | StreetInsider | Clearpoint Neuro Inc. (CLPT) PT Raised to $9 at Stifel |
Latest News for CLPT
ClearPoint Neuro (NASDAQ: CLPT) reported second-quarter 2026 revenue growth while outlining a shift in investment priorities toward clinical capacity, preclinical laboratory services and technologies intended to support commercial-scale neuro drug delivery. Total revenue for the three months ended June 30 was $10.9 million, up 18% from $9.2 million in the prior-year period, CFO Danilo D'Alessandro said.
ClearPoint Neuro's second quarter results were poor across the board, with drug delivery disposables an area of particular weakness. Delays in the ramping of preclinical services at ClearPoint's new facility have also contributed to reduced expectations for 2026. There is now regulatory clarity, though, meaning a revenue inflection as AMT-130 is commercialized is now highly likely in 2027/2028.
ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript
The headline numbers for ClearPoint Neuro (CLPT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.21 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLPT.
U.S. House Trading
No House trades found for CLPT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.